194 related articles for article (PubMed ID: 36322239)
1. Over expression of mTOR gene predicts overall survival in myelodysplastic syndromes.
Maurya N; Mohanty P; Panchal P; Shanmukhaiah C; Vundinti BR
Mol Biol Rep; 2023 Jan; 50(1):235-244. PubMed ID: 36322239
[TBL] [Abstract][Full Text] [Related]
2. Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression.
Sridhar K; Ross DT; Tibshirani R; Butte AJ; Greenberg PL
Blood; 2009 Nov; 114(23):4847-58. PubMed ID: 19801443
[TBL] [Abstract][Full Text] [Related]
3. Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome.
Huang HH; Chen FY; Chou WC; Hou HA; Ko BS; Lin CT; Tang JL; Li CC; Yao M; Tsay W; Hsu SC; Wu SJ; Chen CY; Huang SY; Tseng MH; Tien HF; Chen RH
BMC Cancer; 2019 Jun; 19(1):617. PubMed ID: 31234830
[TBL] [Abstract][Full Text] [Related]
4. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype.
Prats-Martín C; Burillo-Sanz S; Morales-Camacho RM; Pérez-López O; Suito M; Vargas MT; Caballero-Velázquez T; Carrillo-Cruz E; González J; Bernal R; Pérez-Simón JA
Cancer Med; 2020 Jun; 9(11):3637-3646. PubMed ID: 32216059
[TBL] [Abstract][Full Text] [Related]
5. Genomic landscape of CD34+ hematopoietic cells in myelodysplastic syndrome and gene mutation profiles as prognostic markers.
Xu L; Gu ZH; Li Y; Zhang JL; Chang CK; Pan CM; Shi JY; Shen Y; Chen B; Wang YY; Jiang L; Lu J; Xu X; Tan JL; Chen Y; Wang SY; Li X; Chen Z; Chen SJ
Proc Natl Acad Sci U S A; 2014 Jun; 111(23):8589-94. PubMed ID: 24850867
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow macrophages are involved in the ineffective hematopoiesis of myelodysplastic syndromes.
Xing T; Yao WL; Zhao HY; Wang J; Zhang YY; Lv M; Xu LP; Zhang XH; Huang XJ; Kong Y
J Cell Physiol; 2024 Feb; 239(2):e31129. PubMed ID: 38192063
[TBL] [Abstract][Full Text] [Related]
7. What biologic factors predict for transformation to AML?
Bejar R
Best Pract Res Clin Haematol; 2018 Dec; 31(4):341-345. PubMed ID: 30466744
[TBL] [Abstract][Full Text] [Related]
8. Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review.
Bernasconi P
Br J Haematol; 2008 Sep; 142(5):695-708. PubMed ID: 18540941
[TBL] [Abstract][Full Text] [Related]
9. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
Stifter G; Heiss S; Gastl G; Tzankov A; Stauder R
Eur J Haematol; 2005 Dec; 75(6):485-91. PubMed ID: 16313260
[TBL] [Abstract][Full Text] [Related]
10. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells.
Rajapaksa R; Ginzton N; Rott LS; Greenberg PL
Blood; 1996 Dec; 88(11):4275-87. PubMed ID: 8943864
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow stromal cells from MDS and AML patients show increased adipogenic potential with reduced Delta-like-1 expression.
Weickert MT; Hecker JS; Buck MC; Schreck C; Rivière J; Schiemann M; Schallmoser K; Bassermann F; Strunk D; Oostendorp RAJ; Götze KS
Sci Rep; 2021 Mar; 11(1):5944. PubMed ID: 33723276
[TBL] [Abstract][Full Text] [Related]
12. The Effects of Human BDH2 on the Cell Cycle, Differentiation, and Apoptosis and Associations with Leukemia Transformation in Myelodysplastic Syndrome.
Yang WC; Lin SF; Wang SC; Tsai WC; Wu CC; Wu SC
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32344823
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis and classification of myelodysplastic syndromes.
Hasserjian RP; Germing U; Malcovati L
Blood; 2023 Dec; 142(26):2247-2257. PubMed ID: 37774372
[TBL] [Abstract][Full Text] [Related]
14. Novel combinations to improve hematopoiesis in myelodysplastic syndrome.
Syed K; Naguib S; Liu ZJ; Cimmino L; Yang FC
Stem Cell Res Ther; 2020 Mar; 11(1):132. PubMed ID: 32197634
[TBL] [Abstract][Full Text] [Related]
15. Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy.
Radujkovic A; Dietrich S; Andrulis M; Benner A; Longerich T; Pellagatti A; Nanda K; Giese T; Germing U; Baldus S; Boultwood J; Ho AD; Dreger P; Luft T
Int J Cancer; 2016 Sep; 139(6):1402-13. PubMed ID: 27170453
[TBL] [Abstract][Full Text] [Related]
16. Immune Dysregulation and Recurring Mutations in Myelodysplastic Syndromes Pathogenesis.
Matos A; Magalhães SMM; Rauh MJ
Adv Exp Med Biol; 2021; 1326():1-10. PubMed ID: 33385175
[TBL] [Abstract][Full Text] [Related]
17. Biology of the bone marrow microenvironment and myelodysplastic syndromes.
Rankin EB; Narla A; Park JK; Lin S; Sakamoto KM
Mol Genet Metab; 2015; 116(1-2):24-8. PubMed ID: 26210353
[TBL] [Abstract][Full Text] [Related]
18. Myelodysplastic syndrome in children: differentiation from acute myeloid leukemia with a low blast count.
Chan GC; Wang WC; Raimondi SC; Behm FG; Krance RA; Chen G; Freiberg A; Ingram L; Butler D; Head DR
Leukemia; 1997 Feb; 11(2):206-11. PubMed ID: 9009082
[TBL] [Abstract][Full Text] [Related]
19. Morphologic, immunophenotypic, and molecular genetic comparison study in patients with clonal cytopenia of undetermined significance, myelodysplastic syndrome, and acute myeloid leukemia with myelodysplasia-related changes: A single institution experience.
Gao L; Hyter S; Zhang D; Kelting S; Woodroof J; Abdallah AO; Yacoub A; McGuirk J; Abdelhakim H; Godwin AK; Cui W
Int J Lab Hematol; 2022 Aug; 44(4):738-749. PubMed ID: 35352484
[TBL] [Abstract][Full Text] [Related]
20. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
Jhanwar SC
Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
